Archive for the 'Drug Companies' Category

Drug Companies news feed.

Success in Lung Cancer Treatment Gives Hope to Mesothelioma Patients

The latest success concerning a treatment for non- small cell lung cancer (NSCLC) has scientists and researchers hopeful that the same treatment can be applied to mesothelioma victims. The Phase III trial for Alecensa (alectinib), while currently not recruiting participants, is on-going and results thus far have shown to be promising for those with NSCLC.

more

MolMed: NGR-hTNF: increased recruitment rate – with completion foreseen by the end of the year – in the Phase III mesothelioma trial, and new European patent granted

Claudio Bordignon, Chairman of the Board and CEO of MolMed, commented: "The first half-year confirms the positive trend already outlined in the first three months of 2012 in two fields of the Company’s activities. The Phase III trial of NGR-hTNF in mesothelioma recorded a constant increase in the rate of patient recruitment, confirming the forecast

more

Bayer HealthCare receives Orphan Drug Designation for its Anti-Cancer Agent in the U.S. for the Treatment of Mesothelioma

Bayer HealthCare announced today that its investigational anti-cancer agent BAY 94-9343, a mesothelin-targeting antibody-drug conjugate (ADC), has been granted orphan drug status for the treatment of patients with mesothelioma by the U.S. Food and Drug Administration (FDA). This investigational agent is currently in Phase I clinical development. ‘This is an important step in the development

more

Raltitrexed (Tomudex®) in Combination With Cisplatin in the Treatment of MPM Improves Overall Survival Compared to Treatment With Cisplatin Alone

Raltitrexed (Tomudex®) in Combination With Cisplatin in the Treatment of MPM Improves Overall Survival Compared to Treatment With Cisplatin Alone1 MPM is a Rare Cancer, but its Incidence is Expected to Double Over the Next 20 Years in Many Countries2 Raltitrexed is Currently Licensed for the Treatment of MPM in Portugal, Czech Republic and Hungary;

more

MolMed starts Phase III trial of NGR-hTNF in mesothelioma

MolMed S.p.A. (Milan:MLM) announces the treatment of the first patient in a pivotal Phase III trial (NGR015) of its investigational antitumour drug NGR-hTNF in malignant pleural mesothelioma, a condition linked with repeated exposition to asbestos fibers. Claudio Bordignon, MolMed’s chairman and CEO, comments: “We are really proud of this important milestone, as NGR-hTNF may represent

more

microRNAs Shown To Have Powerful Potential as Diagnostic and Prognostic Markers In A Variety Of Cancer Indications

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer Research’s (AACR) 101st Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. from April 17-21, 2010. The posters will include data on

more

Bionomics To Initiate BNC105 Phase II Trial In Mesothelioma Patients

Bionomics, an Australian drug discovery and development company, is set to initiate the second Phase II clinical trial of vascular disrupting agent BNC105 in patients with advanced mesothelioma. Bionomics has already commenced Phase II testing of the anti-cancer properties of BNC105 in renal cancer in the US. The commencement of these two Phase II trials

more

Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients

Demonstrate potential of miR-29c* to act as an independent prognostic factor for time to progression as well as survival after surgery Ability to forecast outcomes for malignant pleural mesothelioma (MPM) may enable clinicians to provide aggressive therapy to the most appropriate patients Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announced

more

Rosetta Genomics and Warnex Medical Laboratories Announce Exclusive Distribution Agreement for Rosetta’s microRNA-based Assays in Canada

Rosetta Genomics, Ltd. (NASDQ:ROSG), the leading developer of microRNA-based molecular diagnostics, and Warnex Medical Laboratories, a division of Warnex Inc. (TSX:WNX), announced today they have signed an exclusive distribution agreement in Canada for three currently-available diagnostic tests. Under the terms of the agreement, Warnex will market Rosetta Genomics’ miRview™ tests. Samples will be sent from

more

Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Rosetta Genomics Ltd. (Nasdaq: ROSG), an innovative molecular diagnostic company, today announced the execution of a license and collaboration agreement under which Rosetta shall grant Prometheus U.S. rights to three recently introduced, microRNA-based cancer diagnostic tests: miRview™ mets, miRview™ squamous and miRview™ meso. The terms

more

Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso

Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. To order the test, physicians may contact 1-888-522-7971, or visit the company’s website http://www.rosettagenomics.com. "I am very excited to

more

Paper in Cell Cycle Reports Alfacell’s ONCONASE® Targets siRNA

Alfacell Corporation (Nasdaq: ACEL) today announced that a paper published in Cell Cycle (2008; Vol. 7, Issue 20) reports that ONCONASE (ranpirnase) targets small interfering RNA (siRNA), likely within the RNA-induced silencing complex (RISC) of the RNA interference (RNAi) mechanism. The paper is the result of research conducted by collaborators at the Brander Cancer Research

more

The European Commission Grants Orphan Drug Designation for Molmed’s Vascular Targeting Agent Arenegyr in the Treatment of Mesothelioma

MolMed S.p.A. (Milan:MLM) announces that the European Commission has granted Orphan Drug designation for MolMed’s investigational new antitumour therapeutic drug ARENEGYR (NGR-hTNFa) in the treatment of malignant pleural mesothelioma (MPM). The Commission decision, dated June 3rd 2008, follows the positive opinion released on April 9 by the Committee for Orphan Medicinal Products (COMP) of the

more

Arenegyr: Key Preliminary Results of Phase II Trials in Mesothelioma and Colorectal Cancer Presented at ASCO

At the 44th ASCO (American Society of Clinical Oncology) Annual Meeting, MolMed S.p.A. (Milan:MLM) will present key preliminary results of two ongoing Phase II clinical trials with ARENEGYR (NGR-hTNF?) in chemo-pretreated patients with malignant pleural mesothelioma (MPM), and in heavily pre-treated patients with advanced colorectal cancer (CRC). Presented during two poster sessions, the preliminary findings

more

Alfacell: Malignant mesothelioma treatment trial fails to meet primary endpoint

Alfacell Corp. late Wednesday said results from its Phase IIIB clinical trial for Onconase, which was being studied as a potential treatment for unresectable malignant mesothelioma, didn’t meet the trial’s primary endpoint. The Somerset, N.J.-based biopharmaceutical company said a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one

more

Last update: March 06, 2014. 08:41:31 pm.